Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

BACKGROUND: The clinical benefit of cetuximab combined with oxaliplatin-based chemotherapy remains under debate. The aim of the present multicenter open-label Phase II study was to explore the efficacy and safety of biweekly administration of cetuximab and mFOLFOX-6 or XELOX as first-line chemothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Soda, Hitoshi, Maeda, Hiromichi, Hasegawa, Junichi, Takahashi, Takao, Hazama, Shoichi, Fukunaga, Mutsumi, Kono, Emiko, Kotaka, Masahito, Sakamoto, Junichi, Nagata, Naoki, Oba, Koji, Mishima, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4607014/
https://www.ncbi.nlm.nih.gov/pubmed/26467662
http://dx.doi.org/10.1186/s12885-015-1685-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4607014/
https://www.ncbi.nlm.nih.gov/pubmed/26467662
http://dx.doi.org/10.1186/s12885-015-1685-z

Ejemplares similares